Advances in Gene Therapy for Inherited Haemoglobinopathies.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical developments without systematic review methodology or primary data.
PubMed 41562671 · doi:10.3390/hematolrep18010004
What was done
This narrative review summarizes the development and clinical translation of hematopoietic stem cell gene therapies for inherited hemoglobinopathies, primarily β-thalassaemia and sickle cell disease. The review discusses lentiviral gene addition, BCL11A silencing, CRISPR/Cas9 gene editing targeting γ-globin repression elements, and emerging base editing technologies.
What was found
The abstract reports no numerical data or statistical measures. Qualitatively, it notes that lentiviral gene addition confers durable expression of functional β-like globin transgenes, leading to transfusion independence in β-thalassaemia and reductions in vaso-occlusive crises in sickle cell disease. Targeted disruption of BCL11A and CRISPR/Cas9-mediated editing have successfully induced fetal hemoglobin (HbF) expression, leading to the clinical approval of the first CRISPR-based therapy for both conditions, while base editing approaches are undergoing clinical evaluation.
Why it matters
This paper provides an overview of the transition of curative genetic therapies from experimental concepts to regulatory-approved treatments for major monogenic red blood cell disorders.
Limits
The abstract contains no quantitative metrics, risk estimates, or details on review search methodology. Key clinical and practical constraints noted include reliance on toxic myeloablative conditioning regimens, specialized manufacturing requirements, and prohibitive treatment costs.
Cited by
- supports Most regulatory approved gene therapies work by gene addition rather than by gene editing.